BillionToOne (United States)
BLLN
$91.65
-38.89%
BillionToOne, Inc. is a molecular diagnostics company specializing in ultrasensitive prenatal genetic testing and oncology liquid biopsy solutions, leveraging its proprietary Quantitative Counting Templates (QCT) platform. The company operates in the competitive medical diagnostics and research industry, positioning itself as a niche innovator with a differentiated product portfolio including UNITY for prenatal screening and Northstar Select/Response for cancer therapy selection and monitoring. The current investor narrative centers on the company's rapid revenue growth, recent transition to profitability, and the market's enthusiasm for its expanding liquid biopsy franchise, as evidenced by a 55% YTD stock surge and strong analyst support. Attention is also focused on the scalability of its QCT platform and the potential for sustained margin expansion as the company captures market share in both prenatal and oncology diagnostics.…
BLLN
BillionToOne (United States)
$91.65
Investment Opinion: Should I buy BLLN Today?
Rating: Buy (with high risk). The thesis is that BillionToOne's rapid revenue growth and improving profitability justify a premium valuation, but investors should be prepared for volatility. The consensus rating is 'Buy' with an average target of $123.86, which is below the current price, suggesting limited upside from here. However, the high target of $145 implies potential upside if the company exceeds expectations. Key supporting data: revenue growth of 83.8% YoY, gross margin of 72.97%, operating margin of 16.45%, and positive net income of $17.97M in Q1 2026. The stock trades at a forward PE of 134.6x, which is high but may be justified if earnings grow as expected. The biggest risks are valuation compression and competitive pressures. This Buy would be downgraded to Hold if revenue growth falls below 50% or if the stock drops below $100, and upgraded to Strong Buy if the stock pulls back to $100 while fundamentals remain strong. Overall, the stock is overvalued relative to its history and peers, but the growth potential may warrant the premium.
Sign up to view all
BLLN 12-Month Price Forecast
The AI assessment is bullish with medium confidence, given the strong fundamental momentum and positive analyst sentiment. However, the extreme valuation and the stock trading above the average target introduce significant risk. The stance would be upgraded to high confidence if the company continues to beat expectations and the stock pulls back to a more reasonable valuation. Conversely, a downgrade to neutral would occur if growth decelerates sharply or if the stock fails to hold above key support levels.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BillionToOne (United States)'s 12-month outlook, with a consensus price target around $122.43 and implied upside of +33.6% versus the current price.
Average Target
$122.43
0 analysts
Implied Upside
+33.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $145
Analyst target range
The wide range between the low and high targets ($90 to $145) indicates substantial disagreement among analysts about the company's future prospects, likely due to the early stage of its profitability and the competitive dynamics in the diagnostics market. The high target assumes continued rapid revenue growth and margin expansion, while the low target may reflect concerns about competitive pressures or slower adoption. Recent institutional actions show no downgrades, with firms like Guggenheim, BTIG, and JP Morgan maintaining or reiterating Buy/Overweight ratings, suggesting that analysts are not yet turning negative. However, the fact that the current price is above the average target suggests that the market is more optimistic than the analyst consensus, which could lead to a correction if the company fails to meet elevated expectations.
Bulls vs Bears: BLLN Investment Factors
BillionToOne presents a compelling growth story with accelerating revenue, improving profitability, and a strong balance sheet, but the valuation is extremely demanding. The bull case is supported by the company's rapid expansion and operational leverage, while the bear case highlights the risk of overvaluation and competitive threats. Currently, the bull side has stronger evidence given the momentum and fundamental improvements, but the key tension is whether the company can sustain its growth trajectory to justify the high multiple. If growth decelerates or margins compress, the stock could face a significant correction, making it a high-risk, high-reward investment.
Bullish
- Revenue growth accelerating to 83.8% YoY: Q1 2026 revenue surged to $108.4M, up 83.8% year-over-year, accelerating from 62.9% growth in Q2 2025. This demonstrates strong commercial adoption of UNITY and Northstar products, with sequential growth from $96.1M in Q4 2025 to $108.4M in Q1 2026.
- Transition to profitability with expanding margins: The company achieved net income of $17.97M in Q1 2026, a dramatic turnaround from a net loss of $3.99M in Q1 2025. Gross margin improved to 72.97% from 64.4% a year ago, while operating margin reached 16.45%, indicating strong operating leverage.
- Strong balance sheet with minimal debt: Debt-to-equity is only 0.23, and the current ratio is 11.69, indicating ample liquidity to fund growth. This financial stability reduces bankruptcy risk and provides flexibility for R&D and commercial expansion.
- Positive analyst sentiment with Buy ratings: The consensus recommendation is 'Buy' with a mean rating of 1.75 (1=Strong Buy, 5=Sell). Analysts at Guggenheim, BTIG, and JP Morgan have reiterated Buy/Overweight ratings, and the average target price of $123.86 implies a 10.6% downside from the current price, but the high target of $145 suggests 4.6% upside.
Bearish
- Extreme valuation with trailing PE of 1,284x: The trailing PE is 1,284.8x, and even the forward PE is 134.6x, indicating that the market is pricing in massive future earnings growth. Any disappointment in growth or margins could lead to a severe de-rating, as seen in many high-multiple growth stocks.
- Stock trades above average analyst target: At $138.60, the stock is 11.9% above the average analyst target of $123.86, suggesting that the market is more optimistic than the analyst consensus. This could lead to a correction if the company fails to exceed already high expectations.
- High short interest and volatility: The short ratio is 3.19, indicating significant bearish positioning. The stock has a max drawdown of -50.81% over the past year, highlighting its volatility and susceptibility to sharp selloffs, as seen in February 2026 when it dropped from $93 to $70 in a week.
- Competitive pressures in diagnostics market: The molecular diagnostics market is highly competitive, with established players like Natera and Guardant Health. BillionToOne's niche position may face challenges from larger competitors with more resources, potentially limiting market share gains and pricing power.
BLLN Technical Analysis
BillionToOne's stock has exhibited a powerful sustained uptrend over the past year, with the current price of $138.60 representing a 55.2% gain YTD and a 68.0% increase over the past six months. The stock is trading at 98.9% of its 52-week range (between $61.96 and $140.21), indicating it is near its all-time high, which typically signals strong momentum but also potential overextension. The price action suggests a robust bullish trend, with the stock consistently making higher highs and higher lows, particularly since the May 2026 breakout above the $100 level.
Beta
—
—
Max Drawdown
-50.8%
Largest decline past year
52-Week Range
$62-$140
Price range past year
Annual Return
—
Cumulative gain past year
| Period | BLLN Return | S&P 500 |
|---|---|---|
| 1m | -22.4% | +2.8% |
| 3m | -1.4% | +4.2% |
| 6m | +1.1% | +11.3% |
| 1y | — | +21.5% |
| ytd | +2.6% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BLLN Fundamental Analysis
BillionToOne's revenue trajectory is accelerating sharply, with the most recent quarter (Q1 2026) reporting revenue of $108.4 million, representing an 83.8% year-over-year growth rate. This marks a significant acceleration from prior quarters, where revenue grew from $36.2 million in Q2 2024 to $66.6 million in Q2 2025, and then to $83.5 million in Q3 2025 and $96.1 million in Q4 2025. The consistent sequential growth across all segments indicates strong commercial adoption of its prenatal and oncology tests, with the UNITY product line likely driving the bulk of revenue expansion. The company's ability to sustain this growth trajectory will be critical, as the diagnostics market is competitive, but the current momentum suggests a favorable investment case.
Quarterly Revenue
$108388000.0B
2026-03
Revenue YoY Growth
+83.8%
YoY Comparison
Gross Margin
73.0%
Latest Quarter
Free Cash Flow
$28087000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BLLN Overvalued?
Given that BillionToOne has positive net income (EPS of $0.39 in Q1 2026), the PE ratio is the primary valuation metric. The trailing PE stands at 1,284.8x, while the forward PE is 134.6x, indicating that the market expects substantial earnings growth in the coming year. The gap between trailing and forward PE reflects the market's anticipation of continued profitability expansion, driven by revenue growth and operating leverage. This is a common pattern for high-growth companies that have recently turned profitable, but the absolute levels are extremely elevated, suggesting high expectations are already priced in.
PE
1284.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
170.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated due to the company's high valuation and recent profitability. The trailing PE of 1,284x and forward PE of 134.6x imply that any earnings miss could trigger a sharp selloff. The company's net margin is only 2.44% (TTM), indicating thin profitability that could be vulnerable to cost increases or pricing pressure. Additionally, the company's revenue is concentrated in a few products, with UNITY likely driving the majority, creating product concentration risk. The current ratio of 11.69 provides a cushion, but the company's cash burn could increase if growth investments accelerate, though the positive free cash flow of $28.1M TTM mitigates this concern.
FAQ
The key risks of holding BLLN are: 1) Valuation risk: The stock is trading at a forward PE of 134.6x, and any disappointment in earnings could lead to a severe multiple compression. 2) Competitive risk: The diagnostics market is competitive, with larger players like Natera and Guardant Health, which could pressure market share and pricing. 3) Operational risk: The company's revenue is concentrated in a few products, and any failure in product adoption or regulatory issues could impact growth. 4) Market risk: The stock has a max drawdown of -50.81%, indicating high volatility, and is sensitive to macro factors and sector rotation. The most severe risk is a combination of these factors leading to a decline to the 52-week low of $61.96, representing a -55% loss from the current price.
The 12-month forecast for BLLN is mixed. The bull case, with a 30% probability, sees the stock reaching $140-$160, driven by continued high growth and margin expansion. The base case, with a 50% probability, expects the stock to trade around $110-$140, aligning with the analyst average target of $123.86. The bear case, with a 20% probability, could see the stock fall to $62-$90 if growth decelerates or competitive pressures intensify. The most likely scenario is the base case, assuming the company maintains its growth trajectory but at a slightly slower pace. Investors should monitor quarterly earnings and guidance for signs of deceleration.
BLLN is overvalued based on traditional valuation metrics. The trailing PE of 1,284.8x and forward PE of 134.6x are extremely high, even for a high-growth company. The PS ratio of 12.29 and EV/Sales of 17.0 also indicate a premium valuation. Compared to peers in the diagnostics industry, which typically trade at PS ratios of 5-10x, BLLN is at a significant premium. The market is pricing in exceptional future growth and profitability, which may be justified given the company's recent performance, but it leaves little room for error. If the company fails to meet high expectations, the stock could see a sharp de-rating.
BLLN is a good buy for investors with a high risk tolerance who believe in the company's growth story. The stock has strong momentum, with a 55.2% YTD gain, and the company is growing revenue at 83.8% YoY. However, the valuation is extremely high, with a forward PE of 134.6x, and the stock trades above the average analyst target of $123.86. The biggest risk is a correction if growth disappoints. For long-term investors, the potential upside is significant, but they must be prepared for volatility. A more prudent approach would be to wait for a pullback to a more reasonable valuation, such as below $100, before initiating a position.
BLLN is more suitable for long-term investment, given its high growth potential and the expanding diagnostics market. The company is in the early stages of its growth cycle, with revenue growing at 83.8% YoY, and it has a strong balance sheet to fund expansion. However, the stock is highly volatile, with a max drawdown of -50.81%, making it unsuitable for short-term trading unless one has a high risk tolerance and can time the market. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the company to realize its potential and for the valuation to become more reasonable. Short-term traders may find opportunities in the volatility, but the risk is substantial.